Sio Gene Therapies to Participate in Upcoming Conferences
03/29/2021 - 08:00 AM
NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences in April. Details can be found below.
Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease Day
Participation: Panel discussion and 1-on-1 investor meetings Panel Title: Emerging Approaches Targeting CNS Indications Like FTD and GM1 Panel Presenter: Pavan Cheruvu, MD, Chief Executive Officer Panel Date & Time: Thursday, April 1, 2021 at 12:00 PM ET Webcast: https://kvgo.com/guggenheim/sio-gene-therapies-april-2021
Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean
Participation: Panel discussion and corporate presentation Panel Title: Innovation: Shortening the Path to Commercialization in Advanced Therapies Panel Presenter: Parag V. Meswani, PharmD, Chief Commercial Officer Date: April 6, 2021 The company presentation and panel discussion will be available to view on-demand throughout the entirety of the conference. Please visit www.meetingonthemed.com for full information including registration.
NTSAD’s 43 rd Annual Family Conference
Participation: Presentations on GM1 and GM2 gangliosidosis (Tay-Sachs/Sandhoff disease) programs Date & Time: April 23, 2021 from 2:00-4:00 PM ET Both sessions will occur concurrently and are available to all attendees who can register for the event here .
The company will also participate in a number of medical events throughout April including the ACMG Annual Clinical Genetics Meeting, AAN 2021 Virtual Annual Meeting, and the Virtual World Orphan Drug Congress USA 2021.
About Sio Gene Therapies
Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. For more information, visit www.siogtx.com .
Contacts:
Media
Josephine Belluardo, Ph.D. info@siogtx.com
Investors and Analysts
Parag V. Meswaniinvestors@siogtx.com
SIOX Rankings
N/A Ranked by Stock Gains
SIOX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
United Kingdom
City
11 12 St Jamess Square
About SIOX
axovant develops transformative gene therapies for patients with life-altering neurologic conditions. our mission is to identify, develop, and bring to market high-impact therapies that have the potential to improve the lives of patients with neurological disorders. our team is made up of leading scientific experts who are passionate about treating neurological conditions and easing the burden of these life-changing disorders for both patients and caregivers. our team is motivated by the promise of novel drug development, and is driven to find more efficient and effective ways to conduct scientific and clinical evaluations that rapidly deliver impactful medicines to patients in need. our leadership team has a track record bringing innovative new neurotherapeutic treatments to a global market, and along with our seasoned board of directors, is fully committed to the responsible pursuit of transformative therapies for some of the world's most difficult conditions.
